Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02972385 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacogenomics of Warfarin in Hispanics and Latinos

StatusUnknown
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 27, 2024 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Recruiting
  2. Notable Primary completion date: Sep 2021 to Sep 2026
    • Study completion date: Sep 2022 to Sep 2026
    v8
  3. Minor Re-verified, no change to tracked fieldsv7
  4. Notable Primary completion date: Sep 2020 to Sep 2021
    • Study completion date: Sep 2020 to Sep 2022
    v6
  5. Notable Primary and study completion dates: Sep 2019 to Sep 2020v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Interventions: Blood Draw (Procedure), Cheek Swab/ Mouthwash sample (Procedure) to Blood Draw (Procedure), Mouthwash sample (Procedure)v4
  2. Minor Re-verified, no change to tracked fieldsv3
  3. Minor Study description shortened, about 111 wordsv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin. Certain genes have also been found to affect warfarin dose. Individuals have variations in these genes, which can help explain why some patients need higher dose and others require less. These factors have been used to better predict a patient's warfarin dose requirement. However, these predictions were created based on Caucasian populations and they may not be accurate in predicting a safe warfarin dose if a patient is not Caucasian. This study aims to identify new genetic variation that affects warfarin dosing in Hispanic and Latino populations and try to better predict a Hispanic or Latino patient's warfarin dose requirement.
Trial Details
NCT Number NCT02972385
Lead Sponsor University of Arizona
Conditions
(from sponsor)
Thrombosis, Hemorrhage
Related terms Hemorrhage, Thrombosis
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov